Advertisement

Loading...

Nuvo Pharmaceuticals Inc.

MRV.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
$1.35
$0.00(0.00%)
Canadian Market opens in 15h 13m

Nuvo Pharmaceuticals Inc. Fundamental Analysis

Nuvo Pharmaceuticals Inc. (MRV.TO) shows weak financial fundamentals with a PE ratio of -19.29, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.
We analyze MRV.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
0.0/100

We analyze MRV.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

MRV.TO struggles to generate sufficient returns from assets.

ROA > 10%
N/A

Valuation Score

Moderate

MRV.TO shows balanced valuation metrics.

PE < 25
-19.29
PEG Ratio < 2
N/A

Growth Score

Weak

MRV.TO faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Weak

MRV.TO carries high financial risk with limited liquidity.

Debt/Equity < 1
N/A
Current Ratio > 1
N/A

Profitability Score

Weak

MRV.TO struggles to sustain strong margins.

ROE > 15%
N/A
Net Margin ≥ 15%
N/A
Positive Free Cash Flow
N/A

Key Financial Metrics

Is MRV.TO Expensive or Cheap?

P/E Ratio

MRV.TO trades at -19.29 times earnings. This suggests potential undervaluation.

-19.29

How Well Does MRV.TO Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How MRV.TO Stacks Against Its Sector Peers

MetricMRV.TO ValueSector AveragePerformance
P/E RatioN/A28.31 N/A
ROEN/A699.00% N/A
Net MarginN/A-131318.00% (disorted) N/A
Debt/EquityN/A0.34 N/A
Current RatioN/A2775.16 N/A
ROAN/A-14513.00% (disorted) N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Nuvo Pharmaceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ